The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of the efficacy of gemcitabine with capecitabine and gemcitabine with erlotinib combination chemotherapy in recurrent or advanced pancreatic cancer as first-line treatment: Single-center experience.
Sang Hoon Chun
Disclosure not yet available
Myung Ah Lee
Disclosure not yet available
Eun Kyoung Jeon
Disclosure not yet available
Ho Jung An
Disclosure not yet available
Tae Ho Hong
Disclosure not yet available
Young Kyoung You
Disclosure not yet available
Dong Goo Kim
Disclosure not yet available
In Seok Lee
Disclosure not yet available